Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1
Open Access
- 1 December 2008
- journal article
- Published by Journal of Molecular Signaling in Journal of Molecular Signaling
- Vol. 3 (1), 18
- https://doi.org/10.1186/1750-2187-3-18
Abstract
The antihyperglycemic drug metformin may have beneficial effects on the prevention and treatment of cancer. Metformin is known to activate AMP-activated protein kinase (AMPK). It has also been shown to inhibit cyclin D1 expression and proliferation of some cultured cancer cells. However, the mechanisms of action by which metformin mediates cell cycle arrest are not completely understood.Keywords
This publication has 39 references indexed in Scilit:
- Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer modelBreast Cancer Research and Treatment, 2008
- The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 levelOncogene, 2008
- Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell GrowthCancer Research, 2007
- Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosisCellular and Molecular Life Sciences, 2007
- Metformin Is an AMP Kinase–Dependent Growth Inhibitor for Breast Cancer CellsCancer Research, 2006
- Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or InsulinDiabetes Care, 2006
- Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic miceExperimental Gerontology, 2005
- Metformin and reduced risk of cancer in diabetic patientsBMJ, 2005
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Prevention of pancreatic cancer induction in hamsters by metforminGastroenterology, 2001